Amphetamine in illegally produced phenylethylamine –intentional action or failed synthesis of a designer drug. Analysis of evidence material by LC/MS (APCI)and GC/MS (EI) methods [PDF]
, 2015 Agnieszka Chłopaś‐Konowałek +2 more
openalex +1 more source
Screening for lung cancer: A systematic review of overdiagnosis and its implications
Molecular Oncology, EarlyView.Low‐dose computed tomography (CT) screening for lung cancer may increase overdiagnosis compared to no screening, though the risk is likely low versus chest X‐ray. Our review of 8 trials (84 660 participants) shows added costs. Further research with strict adherence to modern nodule management strategies may help determine the extent to which ...
Fiorella Karina Fernández‐Sáenz +12 more
wiley +1 more source
Molecular Oncology, EarlyView.Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece +18 more
wiley +1 more source
Characteristic Trends in Prevalence and Use of New Synthetic "Designer" Drugs over the Territory of the Republic of Bashkortostan. [PDF]
, 2016 Azat R. Asadullin +4 more
openalex
Identification of a Cannabinoid Analog as a New Type of Designer Drug in a Herbal Product
, 2009 Nahoko Uchiyama +4 more
openalex +2 more sources
Survivin and Aurora Kinase A control cell fate decisions during mitosis
Molecular Oncology, EarlyView.Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir +2 more
wiley +1 more source
Designer cell therapy for tissue regeneration
Inflammation and RegenerationCancer cell therapy, particularly chimeric antigen receptor (CAR) T-cell therapy for blood cancers, has emerged as a powerful new modality for cancer treatment.
Noyuri Zama, Satoshi Toda
doaj +1 more source
Molecular Oncology, EarlyView.CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir +12 more
wiley +1 more source
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
A new designer drug 5F-ADB activates midbrain dopaminergic neurons but not serotonergic neurons
, 2016 Nozomi Asaoka +7 more
openalex +2 more sources